CD47 and neoplasm: Other strategies have been applied to improve macrophage-mediated anti-tumor responses and reduce the toxicity to normal cells, such as using exosomes harboring SIRPα to block the interaction between CD47 and SIRPα (99) and augmenting the contact interface of CD47-SIRPα via engineering N-terminal peptide extension (80).